← Back to feedRead original →
VERIFIEDET Finance·neutral
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
AI Summary
- ·The Delhi High Court has directed the CDSCO to review a petition against Zydus Lifesciences' semaglutide injection approval.
- ·A diabetes patient has raised concerns regarding the drug's delivery system, citing potential health risks.
- ·The CDSCO is required to make a decision on the patient's representation within two months.